Evidence map›Paper›PMID 28198005›Full record

GuidelineClinical pharmacology and therapeutics2017

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera and 6 more

2 registry-linked trialsAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 350 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
350citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03894878 completednot on this mapstarted 2019, after this paper: background citation

Association Between Risk Scores for Genetic Variants and Percentage of Time in Therapeutic Range for Participants With Atrial Fibrillation, Deep Vein Thrombosis, and/or Intracardiac Thrombosis Taking Warfarin

TypeobservationalSponsorCipherome, Inc.Ran2019 to 2022Enrolled200ConditionsAtrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
NCT05609500 unknown statusnot on this mapstarted 2022, after this paper: background citation

Warfarin Dosage Adjustment for Outside Therapeutic Range: a Linear Regression Model Analysis

Typeobservational_patient_registrySponsorChinese University of Hong KongRan2022 to 2023Enrolled1,200ConditionsWarfarinArmsWarfarin dosage adjustment model
3 · Its place in the literature

Who cites it

350 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Association BetweenMedicina (Kaunas, Lithuania) · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. The role ofExpert review of clinical pharmacology · 2022
    Pooled it
  10. Guideline
  11. Preliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

290 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

J A JohnsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
K E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
L GongDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
M Whirl-CarrilloDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
C M SteinDivision of Clinical Pharmacology Vanderbilt Medical School, Nashville, Tennessee, USA.
S A ScottDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
M T LeeLaboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; National Center for Genome Medicine; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Genomic Medicine Institute, Geisinger Health system, Danville, Pennsylvania, USA.
B F GageDepartment of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
S E KimmelCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
M A PereraDepartment of Medicine, University of Chicago, Chicago, Illinois, USA.
J L AndersonIntermountain Heart Institute, Intermountain Medical Center, and Department of Internal Medicine (Cardiology), University of Utah School of Medicine, Salt Lake City, Utah, USA.
M PirmohamedDepartment of Molecular and Clinical Pharmacology; The Wolfson Centre for Personalised Medicine; Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
T E KleinDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
N A LimdiDepartment of Neurology and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
L H CavallariDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
M WadeliusDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
Predictors of hemorrhage among patients on direct acting oral anticoagulantsR01HL092173 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIMDI, NITA A · 2008 to 2023
$10.4M
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVTR01HL097036 · NHLBI · WASHINGTON UNIVERSITY · PI GAGE, BRIAN F · 2009 to 2015
$5.0M
Clinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6M
Patient Oriented Research in Personalized Antithrombotic TherapyK24HL133373 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIMDI, NITA A · 2016 to 2025
$1.2M
Drug Metabolism Genotypes in Clinical PracticeR01GM109145 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEIN, CHARLES M. · 2014 to 2018
$1.1M
The Pharmacogenomic Control of Clopidogrel Response in Acute Coronary SyndromesK23GM104401 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT, STUART ALEXANDER · 2013 to 2016
$778k
Medical Research Council MR/L006758/1NCATS NIH HHS UL1 TR001427NHGRI NIH HHS U01 HG007269NHLBI NIH HHS K24 HL133373NHLBI NIH HHS R01 HL092173NHLBI NIH HHS R01 HL097036NHLBI NIH HHS U01 HL105198NIGMS NIH HHS K23 GM104401NIGMS NIH HHS R01 GM109145NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Indexed as

AdultAnticoagulantsChildCytochrome P-450 CYP2C9Cytochrome P450 Family 4Dose-Response Relationship, DrugGenotypeHumansPharmacogeneticsVitamin K Epoxide ReductasesWarfarinAnticoagulantsCYP2C9 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP2C9Cytochrome P450 Family 4Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID28198005
PMCPMC5546947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.